A Study of Diarrhea and Intestinal Flora Changes Caused by Pyrotinib in Breast Cancer
试验速览
- 阶段
- 不适用
- 入组人数
- 50
- 试验地点
- 1
- 主要终点
- The quantity of intestinal flora from breast cancer patients' fecal microflora at different follow-up nodes
研究概览
简要总结
By measuring the intestinal flora abundance and bacterial count of patients in the early stage of using pyrotinib to clarify the relationship between diarrhea caused by pyrotinib and changes in intestinal flora in breast cancer patients, the correlation between the change of intestinal flora and the relief of diarrhea are also explored after two-cycle treatment.
详细描述
In recent years, small-molecule tyrosine kinase inhibitors (TKI) have achieved good results in anti-HER2 therapy and have been widely used in clinical practice, such as Breast cancer. However, such drugs can easily cause diarrhea and disorders of intestinal flora , may affect the efficacy of the drug and lead to the occurrence of other diseases.This study is to clarify the connection between the diarrhea caused by pyrotinib and the change of intestinal flora, pave the way for studying on whether the flora affects the efficacy of the drug and whether the flora should be supplemented appropriately in the future.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Female breast cancer patients aged 18-75 years.
- •ECOG performance status of 0 to 1;
- •Known hormone receptor status;
- •HER2 positive breast cancer and previously reveived ≤2 anti-HER2 therapy;
- •Breast cancer patients are about to receive pyrotinib monotherapy or combined with Trastuzumab/Inetetamab and chemotherapy；
- •Patients with adequate organ function before enrollment (no blood transfusion, no white blood cell or platelet-elevating drugs used within 2 weeks before screening): 1) Blood routine:ANC≥1.5×10^9/L; PLT≥90×10^9/L; Hb≥90 g/L；2)Blood biochemistry: TBIL≤1.5×ULN;ALT and AST ≤1.5×ULN; alkaline phosphatase ≤ 2.5×ULN; BUN and Cr≤1.5×ULN；3) Cardiac color Doppler ultrasound:LVEF≥55%；4) 12-lead ECG: QTcF < 470 msec;
- •Signed the informed consent form prior to patient entry, and have good compliance and are willing to cooperate with follow-up.
排除标准
- •patients with Severe heart disease or discomfor;
- •Previous or ongoing use of HER2-targeted tyrosine kinase inhibitors ;
- •Inability to swallow, intestinal obstruction, or other factors that affect the taking and absorption of the drug;
- •Allergy to pyrotinib; history of immunodeficiency, including HIV positive, active HBV/HCV, other acquired or congenital immunodeficiency disease and organ transplantation history;
- •Patients during pregnancy or lactation, patients with childbearing potential tested positive in baseline pregnancy test, or patients unwilling to take effective contraceptive measures throughout the trial and 7 months after the last study medication;
- •patients with intestinal disease, serious concomitant diseases, or other comorbid diseases that will interfere with the planned treatment, or patients not eligible for this study judged by the investigator.
结局指标
主要结局
The quantity of intestinal flora from breast cancer patients' fecal microflora at different follow-up nodes
时间窗: January 2021- December 2022
Fecal samples were collected from patients at each follow-up node to detect the number of bacterial species in the intestinal flora
The abundance of intestinal flora from breast cancer patients' fecal microflora at different follow-up nodes
时间窗: January 2021- December 2022
Fecal samples were collected at each follow-up node to detect the richness of different bacterial species in intestinal flora
次要结局
- Overall Survival（OS）(January 2021- December 2022)
- Disease Control Rate（DCR）(January 2021- December 2022)
- Progression Free Survival (PFS)(January 2021- December 2022)
- Objective Response Rate (ORR)(January 2021- December 2022)